<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90531">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01663753</url>
  </required_header>
  <id_info>
    <org_study_id>2011.670/13</org_study_id>
    <nct_id>NCT01663753</nct_id>
  </id_info>
  <brief_title>Diagnostic Performance of 18F-FDG-PET and Diffusion-weighted MRI in the Assessment of Stage IB to IIB2 Cervical Squamous-cell Carcinoma Response to Concomitant Radiochemotherapy and Brachytherapy</brief_title>
  <acronym>ERRICC</acronym>
  <official_title>Diagnostic Performance of 18F-FDG-PET and Diffusion-weighted MRI in the Assessment of Stage IB to IIB2 Cervical Squamous-cell Carcinoma Response to Concomitant Radiochemotherapy and Brachytherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: The benefit-risk ratio of surgery following concomitant radiochemotherapy and
      brachytherapy remains to be defined in cervical squamous-cell carcinoma (SCC) treatment.
      Scarce studies evaluated the interest of 18F-FDG-PET and MRI in the assessment of response
      to treatment before surgery. A positive predictive value of 75% was found in a small study
      making 18F-FDG-PET a promising tool to assess tumor response and guide surgical approach.
      Diffusion-weighted MRI was also described as an early and sensitive indicator in other
      diseases.

      Objectives: The main objective of this study is to evaluate the sensitivity of 18F-FDG-PET
      in the assessment of cervical cancer response to radiochemotherapy and brachytherapy.
      Secondary objectives focus on 18F-FDG-PET specificity and likehood ratios as well as
      diffusion-weighted MRI diagnostic performances.

      Method: We will conduct a prospective cohort study of 148 women with a stage IB to IIB2
      cervical SCC recruited over 2.5 years in 11 centers in France. Each patient will undergo a
      18F-FDG-PET and a diffusion-weighted MRI before surgery and 8 weeks after completion of the
      brachytherapy. The total follow-up duration (study participation) of patients will be 11
      weeks : inclusion after completion of radiochemotherapy and brachytherapy, 8 weeks until
      18F-FDG-PET and diffusion-weighted MRI, and 3 weeks until surgery.

      Expected results: 18F-FDG-PET and diffusion-weighted MRI could constitute a reliable tool to
      assess response to radiochemotherapy and brachytherapy in cervical SCC treatment. If so it
      could improve clinical practices  and be helpful to decide  whether the patient needs
      surgery or not after radiochemotherapy and brachytherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Sensitivity of 18F-FDG-PET in the assessment of stage IB to IIB2 cervical squamous-cell carcinoma response to concomitant radiochemotherapy and brachytherapy</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>A centralized review will be carried out by 2 independant reviewers, additionally to the initial interpretation. The gold-standard to evaluate tumoral response to radiochemotherapy and brachytherapy will be the anatomopathologic analysis of the hysterectomy piece after surgery. The18F-FDG-PET will be performed 8 weeks following completion of brachytherapy (date of inclusion)and surgery will be performed within 3 weeks after the 18F-FDG-PET.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Specificity and likehood ratios of 18F-FDG-PET in the assessment of stage IB to IIB2 cervical squamous-cell carcinoma response to concomitant radiochemotherapy and brachytherapy</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic performances of diffusion-wheighed MRI in the assessment of stage IB to IIB2 cervical squamous-cell carcinoma response to concomitant radiochemotherapy and brachytherapy</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">148</enrollment>
  <condition>Squamous-cell Cervical Carcinoma Stage IB2 to IIB Without Spread to Lymph Nodes or Metastasis</condition>
  <arm_group>
    <arm_group_label>18F-FDG-PET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The 18F-FDG-PET will be performed 8 weeks following completion of brachytherapy (date of inclusion)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>18F-FDG-PET</intervention_name>
    <arm_group_label>18F-FDG-PET</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients 18 years of age or older

          -  Biopsy-confirmed cervical squamous-cell carcinomas

          -  Stage IB2, IIA ou IIB according to the FIGO staging of cervical carcinomas

          -  No spread to lumbo-aortic lymph nodes

          -  No prior pelvic radiotherapy

          -  No prior cancer treatment

          -  WHO Performance status less than or equal to 1

          -  Beneficiary of a health insurance

          -  Must provide her signed and informed consent

        Exclusion Criteria:

          -  Reccurent or Metastasized cancer

          -  History of uncontrolled cancer, or any cancer treated for less than 5 years (except
             basal cell carcinomas)

          -  Any contraindication to MRI

          -  Know hypersensitivity to Gadolinium, 18F-FDG or one of the excipients

          -  Pregnant or breast feeding patients

          -  Participation in any other clinical trial that could interfere with the study results

          -  Any geographical, social or psychical reasons that could prohibit the ability to
             return for follow-up assessment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GOLFIER François, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Lyon Sud, Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>François GOLFIER, MD, PhD</last_name>
    <phone>478 86 41 79</phone>
    <phone_ext>+33</phone_ext>
    <email>francois.golfier@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne-Marie SCHOTT, MD, PhD</last_name>
    <phone>472 11 51 65</phone>
    <phone_ext>+33</phone_ext>
    <email>anne-marie.schott-pethelaz@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Médecine Nucléaire, Institut de cancérologie de l'Ouest - Site Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie GIRAULT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sylvie GIRAULT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie MESGOUEZ-NEBOUT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service Gynécologie Obstétrique, Hôpital Pellegrin, CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Luc BRUN, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Luc BRUN, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Gynécologie, Hôpital Femme Mère Enfant, Hospices Civils de Lyon</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gery LAMBLIN, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Gery LAMBLIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Oncologique, Centre de Lutte Contre le Cancer Georges-François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles COUTANT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Charles COUTANT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Etienne MARTIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Gynécologie Obstétrique, Hôpital de la Croix-Rousse, Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gil DUBERNARD, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Gil DUBERNARD, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Gynécologie Obstétrique, Hôpital Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Léon BOUBLI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Léon BOUBLI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Gynécologique, Hôpital Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gauthier RATHAT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gauthier RATHAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Radiothérapie, C.R.L.C. Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine KERR, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christine KERR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Gynécologie, Hôpital Archet II</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme DELOTTE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jérôme DELOTTE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Gynécologie Obstétrique, Hôpital Tenon, APHP</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emile DARAI, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Emile DARAI, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Gynécologie, Hôpital Européen Georges Pompidou, APHP</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice LECURU, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Fabrice LECURU, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Gynécologique, Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginie FOURCHOTTE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Virginie FOURCHOTTE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Gynécologie Obstétrique, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François GOLFIER, MD, PhD</last_name>
      <phone>478 86 41 79</phone>
      <phone_ext>+33</phone_ext>
      <email>francois.golfier@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>François GOLFIER, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel RAUDRANT, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Gynécologie Obstétrique, CHU la Milétrie</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier FRITEL, MD</last_name>
    </contact>
    <investigator>
      <last_name>Xavier FRITEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antoine BERGER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Département des Radiations, Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie LESEUR, MD</last_name>
    </contact>
    <investigator>
      <last_name>Julie LESEUR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Gynécologie Obstétrique, CHU Anne de Bretagne Hôpital Sud</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean LEVEQUE, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jean LEVEQUE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie, Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédérique FORESTIER-LEBRETON, MD</last_name>
    </contact>
    <investigator>
      <last_name>Frédérique FORESTIER-LEBRETON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Gynécologique, Institut Curie - Hôpital René Huguenin</name>
      <address>
        <city>Saint-Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roman ROUZIER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Roman ROUZIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Gynécologie Obstétrique, CHU St-Etienne</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Céline CHAULEUR, MD</last_name>
    </contact>
    <investigator>
      <last_name>Céline CHAULEUR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Servce de Médecine Nucléaire, Centre René Gauducheau, CRLCC Nantes Atlantique</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline ROUSSEAU, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Caroline ROUSSEAU, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Département de Radiothérapie, Institut de Cancérologie de la Loire</name>
      <address>
        <city>Saint-Priest en Jarez</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas MAGNE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas MAGNE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Oncologique, Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandoeuvre lès Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric MARCHAL, MD</last_name>
    </contact>
    <investigator>
      <last_name>Frédéric MARCHAL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 14, 2014</lastchanged_date>
  <firstreceived_date>August 9, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>2-fluoro-2-deoxy-d-glucose-positron emission tomography</keyword>
  <keyword>Positron emission tomography</keyword>
  <keyword>Magnetic resonance imaging</keyword>
  <keyword>Diffusion weighted MRI</keyword>
  <keyword>Squamous-cell cervical carcinoma</keyword>
  <keyword>Sensitivity</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
